Leerink Partnrs Predicts Merus' Q1 Earnings (NASDAQ:MRUS)

Merus (NASDAQ:MRUS - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Merus in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the biotechnology company will post earnings per share of ($1.18) for the quarter. The consensus estimate for Merus' current full-year earnings is ($3.89) per share. Leerink Partnrs also issued estimates for Merus' Q2 2025 earnings at ($1.26) EPS and Q3 2025 earnings at ($1.30) EPS.

A number of other equities analysts also recently issued reports on the stock. Wells Fargo & Company began coverage on shares of Merus in a research note on Friday. They issued an "overweight" rating and a $91.00 price target for the company. UBS Group initiated coverage on Merus in a research report on Thursday, October 24th. They set a "buy" rating and a $72.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $85.00 price objective on shares of Merus in a report on Monday, December 2nd. Citigroup boosted their target price on shares of Merus from $89.00 to $97.00 and gave the company a "buy" rating in a report on Monday, December 9th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $85.00 price target on shares of Merus in a research note on Monday, December 9th. One research analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Merus currently has a consensus rating of "Buy" and an average target price of $86.08.

Merus Price Performance

NASDAQ:MRUS traded down $0.82 during trading hours on Friday, hitting $40.43. The company had a trading volume of 284,278 shares, compared to its average volume of 600,879. Merus has a 52 week low of $37.77 and a 52 week high of $61.61. The company has a market capitalization of $2.77 billion, a PE ratio of -10.24 and a beta of 1.11. The stock has a 50-day moving average price of $42.10 and a 200 day moving average price of $47.61.

Hedge Funds Weigh In On Merus

Several institutional investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Merus by 17.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,200 shares of the biotechnology company's stock valued at $4,207,000 after acquiring an additional 12,212 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Merus in the 3rd quarter worth approximately $675,000. State of New Jersey Common Pension Fund D bought a new position in shares of Merus during the 3rd quarter valued at approximately $1,870,000. US Bancorp DE purchased a new stake in Merus during the 3rd quarter valued at $103,000. Finally, HighTower Advisors LLC bought a new stake in Merus in the third quarter worth $358,000. Institutional investors own 96.14% of the company's stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.